You just read:

FDA Grants Orphan Drug Designation to Trovagene's PLK1 Inhibitor, PCM-075, for the Treatment of Acute Myeloid Leukemia (AML)

News provided by

Trovagene, Inc.

Oct 09, 2017, 08:00 ET